pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Analysis of basic patient characteristics according to pain and characteristics related to use of bisphosphonate

Characteristics, N(%) Patients with pain, N(%) Patients without pain, N (%) p-value


(n=20) (n=137)
Age (median, IQR) 66.0 (57.0-73.0) 69.5 (61.0-75.0) 0.529
BMI (median, IQR) 23.1 (21.9-25.1) 22.2 (20.5-24.9) 0.342
SexFemale 17 (85.0) 129 (94.2) 0.232
Menopause YES 13 (76.5) 125 (96.9) 0.001†
No response 3 (17.6) 0 (0.0)
Parity 0 0 (0.0) 5 (3.6) 0.003†
1 or 2 11 (55.0) 65 (47.4)
3 2 (10.0) 56 (40.9)
No response 7 (35.0) 11 (8.0)
Smoking status Non-smoking 17 (85.0) 118 (86.1) 0.690
Ex-smoking 2 (10.0) 8 (5.8)
Currently smoking 0 (0.0) 6 (4.4)
No response 1 (5.0) 5 (3.6)
Alcohol status Less than once a week 14 (70.0) 103 (75.2) 0.822
More than twice a week 1 (5.0) 8 (5.8)
No response 5 (25.0) 26 (19.0)
Exercise status Less than 20 minutes, 3 times a week, 11 (55.0) 45 (32.8) 0.059
More than 20 minutes, 3 times a week 8 (40.0) 89 (65.0)
No response 1 (5.0) 3 (2.2)
Medication Alendronate 6 (30.0) 53 (38.7)
Risedronate 9 (45.0) 64 (46.7)
Ibandronate 4 (20.0) 19 (13.9)
No response 1 (5.0) 1 (0.7)
Dosing frequency Once daily 2 (10.0) 5 (3.6) 0.214
Once a week 9 (45.0) 75 (54.7)
Once a month 8 (40.0) 55 (40.1)
No response 1 (5.0) 2 (1.5)
Start of medication Within the last 1 month 3 (15.0) 24 (17.5) 0.643
Within the last 3 months 2 (10.0) 12 (8.8)
Within the last 6 months 2 (10.0) 18 (13.1)
Within the last 1 year 9 (45.0) 71 (51.8)
No response 4 (20.0) 12 (8.8)
Injection for osteoporosis treatment 5 (25.0) 21 (15.3) 0.123
Pain after injection 3 (60.0) 4 (19.0) 0.101
Combined medication NSAIDs 6 (30.0) 26 (19.0) 0.248
Corticosteroid 2 (10.0) 5 (3.6) 0.565
Statin 8 (40.0) 53 (38.7) 0.910
DPP-4 inhibitor 3 (15.0) 10 (7.3) 0.652
Others 6 (30.0) 43 (31.4) 0.901
Comorbidity Cancer 0 (0.0) 7 (5.1) 0.597
Rheumatoid arthritis 1 (5.0) 3 (2.2) 0.424
Osteoarthritis 4 (20.0) 31 (22.6) 1.000
Gout 0 (0.0) 1 (0.7) 1.000
Diabetes 3 (15.0) 27 (19.7) 0.767
Hyperlipidemia 9 (45.0) 54 (39.4) 0.634
Others 8 (40.0) 31 (22.6) 0.103

*Statistical differences between groups are tested using t-test age for age, Wilcoxon rank sum test for BMI, and chi-square test or Fisher’s exact test for categorical variables

p-value < 0.05

Abbreviation: SD, standard deviation, BMI, body mass index, NSAIDs, non-steroidal anti-inflammatory drugs, DPP-4, dipeptidyl peptidase-4; IQR, interquartile range

Korean J Clin Pharm 2021;31:180-7 https://doi.org/10.24304/kjcp.2021.31.3.180
© 2021 Korean J Clin Pharm